Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers

Bibliography

• Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985;12(Suppl A):21-33
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7(8):573-84
   PubMed Web of Science ®Google Scholar
• Alva AS, Matin SF, Lerner SP, Siefker-Radtke AO. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol 2012;9(5):266-73
   PubMedGoogle Scholar
• Bookman MA. First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol 2012;55(1):96-113
   PubMed Web of Science ®Google Scholar
• Loriot Y, Mordant P, Deutsch E, et al. Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009;6(9):528-34
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30(14):1692-8
   PubMed Web of Science ®Google Scholar
• Matos CS, de Carvalho AL, Lopes RP, Marques MP. New strategies against prostate cancer–Pt(II)-based chemotherapy. Curr Med Chem 2012;19(27):4678-87
   PubMedGoogle Scholar
• Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs 2007;16(7):1009-21
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11(10):719-25
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22(11):2159-66
   PubMed Web of Science ®Google Scholar
• Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol 2006;4(6):459-68
   PubMedGoogle Scholar
• Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62(4):220-41
   PubMed Web of Science ®Google Scholar
• Enomoto T, Kuragaki C, Yamasaki M, et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 2003;22:abstract 1797
   Google Scholar
• Itamochi H, Kigawa J, Sultana H, et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002;93(6):723-8
   PubMedGoogle Scholar
• Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94(2):138-43
   PubMedGoogle Scholar
• Kim A, Enomoto T, Serada S, et al. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 2009;125(10):2316-22
   PubMed Web of Science ®Google Scholar
• Miao Y, Cai B, Liu L, et al. Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009;19(9):1545-9
   PubMedGoogle Scholar
• Kim A, Serada S, Enomoto T, Naka T. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Expert Opin Ther Targets 2010;14(9):963-71
   PubMed Web of Science ®Google Scholar
• Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005;6(6):449-61
   PubMed Web of Science ®Google Scholar
• Kaetzel MA, Chan HC, Dubinsky WP, et al. A role for annexin IV in epithelial cell function. Inhibition of calcium-activated chloride conductance. J Biol Chem 1994;269(7):5297-302
   PubMedGoogle Scholar
• Kaetzel MA, Mo YD, Mealy TR, et al. Phosphorylation mutants elucidate the mechanism of annexin IV-mediated membrane aggregation. Biochemistry 2001;40(13):4192-9
   PubMedGoogle Scholar
• Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002;82(2):331-71
   PubMedGoogle Scholar
• Matsuzaki S, Enomoto T, Serada S, et al. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. Int J Cancer 2013; Epub ahead of print
   Google Scholar
• Jeon YJ, Kim DH, Jung H, et al. Annexin A4 interacts with the NF-kappaB p50 subunit and modulates NF-kappaB transcriptional activity in a Ca2+-dependent manner. Cell Mol Life Sci 2010;67(13):2271-81
   PubMed Web of Science ®Google Scholar
• Alfonso P, Canamero M, Fernandez-Carbonie F, et al. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 2008;7(10):4247-55
   PubMedGoogle Scholar
• Duncan R, Carpenter B, Main LC, et al. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 2008;98(2):426-33
   PubMed Web of Science ®Google Scholar
• Sitek B, Luttges J, Marcus K, et al. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 2005;5(10):2665-79
   PubMedGoogle Scholar
• Zimmermann U, Balabanov S, Giebel J, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett 2004;209(1):111-18
   PubMed Web of Science ®Google Scholar
• Rescher U, Gerke V. Annexins–unique membrane binding proteins with diverse functions. J Cell Sci 2004;117(Pt 13):2631-9
   PubMedGoogle Scholar
• Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008;216(2):131-40
   PubMedGoogle Scholar
• Hedhli N, Falcone DJ, Huang B, et al. The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol 2012;2012:406273
   PubMedGoogle Scholar
• Liemann S, Huber R. Three-dimensional structure of annexins. Cell Mol Life Sci 1997;53(6):516-21
   PubMedGoogle Scholar
• Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun 2004;322(4):1166-70
   PubMedGoogle Scholar
• Zanotti G, Malpeli G, Gliubich F, et al. Structure of the trigonal crystal form of bovine annexin IV. Biochem J 1998;329(Pt 1):101-6
   PubMedGoogle Scholar
• Newman RH, Leonard K, Crumpton MJ. 2D crystal forms of annexin IV on lipid monolayers. FEBS Lett 1991;279(1):21-4
   PubMedGoogle Scholar
• Pigault C, Follenius-Wund A, Schmutz M, et al. Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol 1994;236(1):199-208
   PubMedGoogle Scholar
• Chan HC, Kaetzel MA, Gotter AL, et al. Annexin IV inhibits calmodulin-dependent protein kinase II-activated chloride conductance. A novel mechanism for ion channel regulation. J Biol Chem 1994;269(51):32464-8
   PubMedGoogle Scholar
• Sohma H, Ohkawa H, Hashimoto E, et al. Alteration of annexin IV expression in alcoholics. Alcohol Clin Exp Res 2001;25(6 Suppl):55S-8S
   PubMedGoogle Scholar
• Ohkawa H, Sohma H, Sakai R, et al. Ethanol-induced augmentation of annexin IV in cultured cells and the enhancement of cytotoxicity by overexpression of annexin IV by ethanol. Biochim Biophys Acta 2002;1588(3):217-25
   PubMedGoogle Scholar
• Lin LL, Chen CN, Lin WC, et al. Annexin A4: a novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. Proteomics Clin Appl 2008;2(4):619-34
   PubMed Web of Science ®Google Scholar
• Deng S, Wang J, Hou L, et al. Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett 2013;5(1):107-12
   PubMedGoogle Scholar
• Yamashita T, Nagano K, Kanasaki S, et al. Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem Biophys Res Commun 2012;421(1):140-4
   PubMedGoogle Scholar
• Choi CH, Sung CO, Kim HJ, et al. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. Hum Pathol 2013;44(6):1017-23
   PubMed Web of Science ®Google Scholar
• Han EK, Tahir SK, Cherian SP, et al. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000;83(1):83-8
   PubMed Web of Science ®Google Scholar
• Basak S, Behar M, Hoffmann A. Lessons from mathematically modeling the NF-kappaB pathway. Immunol Rev 2012;246(1):221-38
   PubMedGoogle Scholar
• Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18(49):6938-47
   PubMed Web of Science ®Google Scholar
• Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107(3):241-6
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2(4):301-10
   PubMed Web of Science ®Google Scholar
• Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012;12(2):121-32
   PubMed Web of Science ®Google Scholar
• Campbell KA, Minashima T, Zhang Y, et al. Annexin 6 interacts with p65 and stimulates NF-kappaB activity and catabolic events in articular chondrocytes. Arthritis Rheum 2013;65(12):3120-9
   PubMedGoogle Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31(15):1869-83
   PubMed Web of Science ®Google Scholar
• Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993;67(6):1171-6
   PubMed Web of Science ®Google Scholar
• Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3(1):1-19
   PubMed Web of Science ®Google Scholar
• Baekelandt MM, Holm R, Nesland JM, et al. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000;20(2B):1061-7
   PubMed Web of Science ®Google Scholar
• Hille S, Rein DT, Riffelmann M, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs 2006;17(9):1041-4
   PubMedGoogle Scholar
• Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3(7):833-8
   PubMed Web of Science ®Google Scholar
• Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 2004;93(1):98-106
   PubMed Web of Science ®Google Scholar
• Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003;22(3):188-99
   PubMedGoogle Scholar
• Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57(16):3537-47
   PubMed Web of Science ®Google Scholar
• Yamasaki M, Makino T, Masuzawa T, et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 2011;104(4):707-13
   PubMed Web of Science ®Google Scholar
• Koike K, Kawabe T, Tanaka T, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997;57(24):5475-9
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Buchholz JK, et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55(5):929-37
   PubMed Web of Science ®Google Scholar
• Guminski AD, Balleine RL, Chiew YE, et al. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 2006;100(2):239-46
   PubMed Web of Science ®Google Scholar
• Surowiak P, Materna V, Kaplenko I, et al. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 2006;12(23):7149-58
   PubMedGoogle Scholar
• Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996;56(18):4124-9
   PubMed Web of Science ®Google Scholar
• Liedert B, Materna V, Schadendorf D, et al. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003;121(1):172-6
   PubMed Web of Science ®Google Scholar
• Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004;94(1):152-60
   PubMedGoogle Scholar
• Korita PV, Wakai T, Shirai Y, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 2010;23(4):965-72
   PubMed Web of Science ®Google Scholar
• Halon A, Materna V, Donizy P, et al. MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor. Arch Gynecol Obstet 2013;287(3):563-70
   PubMedGoogle Scholar
• Samimi G, Varki NM, Wilczynski S, et al. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003;9(16 Pt 1):5853-9
   PubMedGoogle Scholar
• Safaei R, Holzer AK, Katano K, et al. The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 2004;98(10):1607-13
   PubMedGoogle Scholar
• Rabik CA, Maryon EB, Kasza K, et al. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 2009;64(1):133-42
   PubMedGoogle Scholar
• Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62(22):6559-65
   PubMedGoogle Scholar
• Samimi G, Safaei R, Katano K, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004;10(14):4661-9
   PubMed Web of Science ®Google Scholar
• Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009;15(11):3770-80
   PubMed Web of Science ®Google Scholar
• Kalayda GV, Wagner CH, Buss I, et al. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 2008;8:175
   PubMed Web of Science ®Google Scholar
• Aida T, Takebayashi Y, Shimizu T, et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol 2005;97(1):41-5
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Tanaka T, Kurokawa H, et al. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Anticancer Res 2007;27(4B):2209-16
   PubMedGoogle Scholar
• Petris MJ, Mercer JF, Culvenor JG, et al. Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. EMBO J 1996;15(22):6084-95
   PubMedGoogle Scholar
• Roelofsen H, Wolters H, Van Luyn MJ, et al. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. Gastroenterology 2000;119(3):782-93
   PubMedGoogle Scholar
• Phueaouan T, Chaiyawat P, Netsirisawan P, et al. Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer. Oncol Rep 2013;30(6):2929-36
   PubMedGoogle Scholar
• Lokman NA, Elder AS, Ween MP, et al. Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget 2013;4(8):1199-211
   PubMed Web of Science ®Google Scholar
• Sato T, Kita K, Sugaya S, et al. Extracellular release of annexin II from pancreatic cancer cells and resistance to anticancer drug-induced apoptosis by supplementation of recombinant annexin II. Pancreas 2012;41(8):1247-54
   PubMedGoogle Scholar
• Kagawa S, Takano S, Yoshitomi H, et al. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res 2012;178(2):758-67
   PubMedGoogle Scholar
• Wu N, Liu S, Guo C, et al. The role of annexin A3 playing in cancers. Clin Transl Oncol 2013;15(2):106-10
   PubMedGoogle Scholar
• Liu YF, Xiao ZQ, Li MX, et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 2009;217(1):54-64
   PubMedGoogle Scholar
• Kollermann J, Schlomm T, Bang H, et al. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 2008;54(6):1314-23
   PubMed Web of Science ®Google Scholar
• Yan X, Yin J, Yao H, et al. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res 2010;70(4):1616-24
   PubMed Web of Science ®Google Scholar
• Yin J, Yan X, Yao X, et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med 2012;16(2):337-48
   PubMed Web of Science ®Google Scholar
• Furge LL, Chen K, Cohen S. Annexin VII and annexin XI are tyrosine phosphorylated in peroxovanadate-treated dogs and in platelet-derived growth factor-treated rat vascular smooth muscle cells. J Biol Chem 1999;274(47):33504-9
   PubMedGoogle Scholar
• Farnaes L, Ditzel HJ. Dissecting the cellular functions of annexin XI using recombinant human annexin XI-specific autoantibodies cloned by phage display. J Biol Chem 2003;278(35):33120-6
   PubMedGoogle Scholar
• Jorgensen CS, Levantino G, Houen G, et al. Determination of autoantibodies to annexin XI in systemic autoimmune diseases. Lupus 2000;9(7):515-20
   PubMedGoogle Scholar
• Song J, Shih Ie M, Salani R, et al. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 2007;13(22 Pt 1):6842-9
   PubMedGoogle Scholar
• Song J, Shih Ie M, Chan DW, Zhang Z. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia 2009;11(6):605-14; 1 p following 14
   PubMedGoogle Scholar
• Kim HJ, So HS, Lee JH, et al. Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Free Radic Biol Med 2006;40(10):1810-19
   PubMed Web of Science ®Google Scholar
• Wei R, Zhang Y, Shen L, et al. Comparative proteomic and radiobiological analyses in human lung adenocarcinoma cells. Mol Cell Biochem 2012;359(1-2):151-9
   PubMedGoogle Scholar